Rezūm therapy for ≥80‐ mL benign prostatic enlargement: a large, multicentre cohort study
- 7 May 2022
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 130 (4) , 522-527
Abstract
Objective: To evaluate the efficacy and safety of Rezūm therapy in benign prostatic hyperplasia (BPH) patients with prostates ≥80 mL. Methods: A prospective registry was established at two high‐volume Canadian centres. Patients had baseline medical history documented, and uroflowmetry and questionnaire results were recorded over 12 months. Results: Eighty‐three patients (median [interquartile range {IQR}] age 69.2 [63.2, 74.8] years) with a prostate size ≥80 mL were included. The median (IQR) prostate volume was 100.0 (88.5, 115.0) mL and 65% had a median lobe. Twenty‐one patients had prior urinary retention. The median (IQR) number of injections was 13 (11, 15) and catheterization duration was 9 (7, 14) days. International Prostate Symptom Scores (IPSSs) improved by 24%, 57% and 59% at 1, 3 and 12 months, respectively ( P < 0.001). IPSS Quality of Life (QoL) scores improved by 27%, 56% and 70% at these same timepoints ( P < 0.001). Maximum urinary flow rate improved by 55% at 3 months ( P = 0.002) and 59% at 12 months, and post‐void residual urine volume improved by 58% at 3 months ( P = 0.006). BPH Impact Index scores improved by 57% at 3 months and 71% at 12 months. International Index of Erectile Function‐15 scores improved by 15% at 6 months, and Male Sexual Health Questionnaire for Ejaculatory Dysfunction scores improved by 22.4% at 1 month. Three patients (3.6%) noted reduced/anejaculation. No events of Clavien–Dindo grade III or higher occurred. Conclusion: This study demonstrates, for the first time, the safety and efficacy of Rezūm therapy in large glands >80 mL. IPSS improved by 59% and IPSS QoL score improved by 70% at 12 months. Objective maximum urinary flow measures improved at 12 months by 59%, while erectile and ejaculatory function remained preserved.Keywords
This publication has 15 references indexed in Scilit:
- Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasiaTherapeutic Advances in Urology, 2018
- Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80–150 cc)International Journal Of Impotence Research, 2018
- Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 updateCanadian Urological Association Journal, 2018
- Benign prostatic hyperplasiaNature Reviews Disease Primers, 2016
- Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaJournal of Urology, 2016
- National Trends of Simple Prostatectomy for Benign Prostatic Hyperplasia With an Analysis of Risk Factors for Adverse Perioperative OutcomesUrology, 2015
- Rezūm System Water Vapor Treatment for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Validation of Convective Thermal Energy Transfer and Characterization With Magnetic Resonance Imaging and 3-Dimensional RenderingsUrology, 2015
- Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm® system: evaluation of acute ablative capabilities in the human prostateResearch and Reports in Urology, 2015
- Development and Validation of Four-Item Version of Male Sexual Health Questionnaire to Assess Ejaculatory DysfunctionUrology, 2007
- The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunctionUrology, 1997